Mecasermin
Mechanism :
Mecasermin is an insulin-like growth factor (IGF-1) produced using recombinant DNA technology to replace endogenous IGF-1.
Indication :
- Primary insulin-like growth factor-1 deficiency
Contraindications :
Hypersensitivity to mecasermin or any component of the formulation; patients with closed epiphyses; active or suspected neoplasia; intravenous administration.
Dosing :
Subcutaneous:
Children ≥2 years and Adolescents:
Initial: 0.04-0.08 mg/kg twice daily; if tolerated for 7 days, may increase by 0.04 mg/kg/dose. Maximum dose: 0.12 mg/kg twice daily.
Adverse Effect :
Heart murmur, dizziness, headache, seizure, hypoglycemia, lipohypertrophy (injection site), thymus hypertrophy, vomiting, arthralgia, limb pain, abnormal tympanometry, fluid in ear (middle ear), hyperacusis, otalgia, otitis media, serous otitis media, tonsillar hypertrophy.
Interaction :
Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.
Hepatic Dose :
No dosage adjustments are recommended.